



Corporate Profile


Key Facts

- Substantial revenues from licensed and marketed products
- Partnered programmes (with AstraZeneca, Genzyme, Tolerx/GSK, Cougar Biotechnology and others)
- A broad pipeline of development programmes targeting cancer, neurological and other disorders
- Polyclonal manufacturing capability
- ~290 employees in Europe, North America, Australia and Japan
- LSE listed ("BGC"), FTSE 250 constituent; market cap ~£460m (03/08/09)
- Acquisition of Protherics PLC completed December 2008

Overview

BTG is an international specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. The company is also seeking to acquire new products to develop and market to hospital specialists, and is building a sustainable business financed by revenues from sales of its critical care products and from royalties and milestone payments on partnered products.

Development Pipeline



Leadership Team

Dr Louise Makin
Chief Executive Officer

Rolf Soderstrom
Chief Financial Officer

Matthew Gantz
Executive Vice President, US


Dr Guenter R Janhofer
Head of Development

Dr Richard Mason
Head of Business Development

James Christie
Operations Director

Yvonne Rogers
Director of Human Resources

Partnered Programmes



Strategy

Following the acquisition of Protherics PLC in December 2008, BTG's key corporate goals are to:

- Establish US commercial operations focused on hospital specialist products in preparation for:
 - the return of distribution rights to the critical care products CroFab™ and DigiFab™ in 2010
 - the potential approval of Voraxaze™ for high dose methotrexate toxicity - anticipated H2 2010
- Acquire further products targeting hospital specialists
- Build value in and commercialise the development pipeline

Marketed Products

Product	Partner	Indication
BeneFIX®	Wyeth	The first recombinant Factor IX therapy approved for the treatment of haemophilia B
CroFab™	Nycomed in the US until 2010; Swedish Orphan International AB for Nordic countries; BTG for other EU countries and the rest of the world	An antidote used to treat mild or moderate envenomation from Crotalid snakes, which includes rattlesnakes, found in the US
Two-Part Hip Cup	All major orthopaedic companies, including Zimmer Holdings Inc, Stryker Corporation, Smith & Nephew Inc and Biomet Inc	Prosthetic hip joint replacement which allows an improved range of motion that helps to avoid dislocation
Campath®	Genzyme Corporation	A humanised anti-lymphocyte antibody approved for treatment of B-cell chronic lymphocytic leukaemia
DigiFab™	Nycomed for the US until 2010; Beacon Pharmaceuticals in the EU (excluding Scandinavia/Germany); local partners and BTG for the rest of the world	An antidote to treat patients with life-threatening digoxin (digitalis) toxicity or overdose
Three-Part Knee	Biomet Merck Ltd and Corin Ltd	Unicompartmental knee joint replacement designed to give more freedom of movement similar to that of a natural knee

Although not an approved or marketed drug, ViperaTAb™, an antidote for the treatment of snakebites from the European common adder (Vipera berus) is also available in Europe on a named patient basis.

August 2009

Revenues from Marketed Products

Gross Revenues (year ended 31 March 2009)

BeneFIX®	£24.7m
CroFab™	£9.2m*
Two-Part Hip Cup	£10.3m
Campath®	£5.6m
DigiFab™	£2.2m*
MRC Humanisation IP	£4.9m
Voraxaze™	£1.0m*
Three-Part Knee	£4.0m

**Figures only include sales from 4/12/08 to 31/3/09 following the Protherics acquisition*

Major Shareholders (3%+)

As of August 2009

INVESCO Asset Management Ltd
M&G Investment Management Ltd
Schroder Investment Management (UK) Ltd
Aviva Investors
Legal & General Investment Management Ltd
Standard Life Investments Ltd

Analyst Research

Sam Fazeli/Tracey Butcher
Piper Jaffray
Gary Waanders
Nomura Code
Robin Davison
Edison Investment Research
Elizabeth Klein
Singer Capital Markets
Paul Cuddon
KBC Peel Hunt
Stefan Hamill
Noble Investments
Keith Redpath
FinnCap

Contact

Andy Burrows
+44 (0)20 7575 1741
andy.burrows@btgplc.com